First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma
暂无分享,去创建一个
P. Wen | T. Cloughesy | T. Wilson | K. Morrissey | E. Lee | E. Gerstner | A. Coimbra | B. Ellingson | L. Mueller | Xuyang Lu | A. Olivero | J. Rodón | T. Wilson
[1] T. Wurdinger,et al. Patient-Derived Glioma Models: From Patients to Dish to Animals , 2019, Cells.
[2] L. Deangelis,et al. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma , 2019, Journal of Neuro-Oncology.
[3] H. Fine,et al. Modeling Patient-Derived Glioblastoma with Cerebral Organoids. , 2019, Cell reports.
[4] Sankha S. Basu,et al. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Jill S Barnholtz-Sloan,et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.
[6] F. Lieberman,et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.
[7] J. Baselga,et al. Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. , 2017, Cancer discovery.
[8] G. Hortobagyi,et al. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2− advanced breast cancer: results from BOLERO-2 , 2017, British Journal of Cancer.
[9] Susan M. Chang,et al. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. , 2017, Journal of oncology practice.
[10] L. Rangell,et al. Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma , 2016, Drug Metabolism and Disposition.
[11] A. Garg,et al. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Beijnen,et al. PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models , 2016, Clinical Cancer Research.
[13] F. Gosselin,et al. Development of an Efficient, Safe, and Environmentally Friendly Process for the Manufacture of GDC-0084 , 2016 .
[14] S. Sideris,et al. Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR , 2016, ACS medicinal chemistry letters.
[15] P. Wen,et al. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. , 2015, Neuro-oncology.
[16] Richard Bourgon,et al. High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing , 2014, Clinical Cancer Research.
[17] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[18] M. Prados,et al. Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study. , 2013 .
[19] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[20] W. Mason,et al. Phase II study of PX-866 in recurrent glioblastoma. , 2012, Neuro-oncology.
[21] Zev A. Binder,et al. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells , 2011, Oncotarget.
[22] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] W. Oyen,et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[24] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[25] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[26] C. Schnell,et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. , 2008, Cancer research.
[27] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[28] Holger Gerhardt,et al. Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration , 2008, Nature.
[29] S. Horvath,et al. Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.
[30] David M Sabatini,et al. Defining the role of mTOR in cancer. , 2007, Cancer cell.
[31] Joel Karp,et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] L. Cantley,et al. Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.
[33] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[34] J. Miyazaki,et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. , 2005, Genes & development.
[35] F. Khuri,et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.
[36] B. Scheithauer,et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Susan M. Chang,et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.
[38] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[39] P. Finan,et al. Therapeutic potential of phosphoinositide 3-kinase inhibitors. , 2003, Chemistry & biology.
[40] Eilon D. Kirson,et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma , 2017 .
[41] P. Wen,et al. 5 - Malignant Gliomas in Adults , 2010 .
[42] W. Weiss,et al. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. , 2010, Current topics in microbiology and immunology.
[43] L. Cantley. The role of phosphoinositide 3-kinase in human disease. , 2004, Harvey lectures.